- Home
- TOYO vs IVA Comparison
TOYO vs IVA Comparison
Compare TOYO & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- IVA
- Stock Information
- Founded
- TOYO 2022
- IVA 2011
- Country
- TOYO Japan
- IVA France
- Employees
- TOYO N/A
- IVA N/A
- Industry
- TOYO
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- IVA Health Care
- Exchange
- TOYO NYSE
- IVA Nasdaq
- Market Cap
- TOYO 115.2M
- IVA 117.3M
- IPO Year
- TOYO N/A
- IVA 2020
- Fundamental
- Price
- TOYO $2.70
- IVA $2.42
- Analyst Decision
- TOYO
- IVA Strong Buy
- Analyst Count
- TOYO 0
- IVA 3
- Target Price
- TOYO N/A
- IVA $17.67
- AVG Volume (30 Days)
- TOYO 29.2K
- IVA 613.1K
- Earning Date
- TOYO 08-21-2024
- IVA 09-25-2024
- Dividend Yield
- TOYO N/A
- IVA N/A
- EPS Growth
- TOYO N/A
- IVA N/A
- EPS
- TOYO 0.24
- IVA N/A
- Revenue
- TOYO $62,377,390.00
- IVA $20,652,523.00
- Revenue This Year
- TOYO N/A
- IVA N/A
- Revenue Next Year
- TOYO N/A
- IVA $469.85
- P/E Ratio
- TOYO $10.78
- IVA N/A
- Revenue Growth
- TOYO N/A
- IVA N/A
- 52 Week Low
- TOYO $1.36
- IVA $1.53
- 52 Week High
- TOYO $15.61
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- IVA 60.27
- Support Level
- TOYO N/A
- IVA $2.19
- Resistance Level
- TOYO N/A
- IVA $2.85
- Average True Range (ATR)
- TOYO 0.00
- IVA 0.17
- MACD
- TOYO 0.00
- IVA 0.09
- Stochastic Oscillator
- TOYO 0.00
- IVA 65.60
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.